CATB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 Sep 2021 @ 00:00):

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States...

Stats
Today's Volume	98 872.00
Average Volume	528 916
Market Cap	234.86M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.105 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2021-06-08	Harshbarger Benjamin	Buy	200 000	Stock Option (right to buy)
2021-06-02	Callori Fred	Buy	85 000	Stock Option (right to buy)
2021-06-02	Violin Jonathan	Buy	85 000	Stock Option (right to buy)
2021-06-02	Clauser Noah	Buy	600 000	Stock Option (right to buy)
2021-06-02	Kishbauch Michael D	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 86 transactions
Buy: 7 288 895 \| Sell: 328 827

Volume Correlation

Long: -0.05 (neutral)

Short: 0.18 (neutral)

Signal:(67.933) Neutral

Catabasis Pharmaceuticals Correlation

10 Most Positive Correlations
VNET	0.911
TTOO	0.908
LSXMA	0.905
TTGT	0.904
EGAN	0.904
RUBY	0.903
LSXMK	0.903
AVIR	0.902
ACRS	0.901
PTEN	0.901

10 Most Negative Correlations
PAE	-0.908
SCR	-0.902
EBSB	-0.898
TYHT	-0.894
RAM	-0.89
SGEN	-0.88
BCTG	-0.88
ZGNX	-0.879
CPTA	-0.878
MOSY	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catabasis Pharmaceuticals Correlation - Currency/Commodity

0.46
( neutral )

0.57
( weak )

0.24
( neutral )

0.29
( neutral )

-0.12
( neutral )

-0.01
( neutral )

Financial Reports:

No articles found.

Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.